Phaseline

Targets › IL1RAP

IL1RAP (Interleukin-1 receptor accessory protein): drug programs, companies and trials

5 programs from 5 companies in 8 trials: 3 Phase 1, 3 Phase 3, 1 Phase 4, 1 Phase 2; Oncology, Immunology, Respiratory; next expected readout Jun 2027.

Coreceptor for IL1RL2 in the IL-36 signaling system (By similarity). Coreceptor with IL1R1 in the IL-1 signaling system. (UniProt, Q9NPH3)

Open in Phaseline: the race on IL1RAP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
LEO PharmaSpesolimab
IL36 receptor antagonist
IL36R, IL1RAPPhase 4Generalized Pustular Psoriasis; Pyoderma GangrenosumSep 2027
RocheAstegolimab
IL-33 receptor (ST2) inhibitor
IL1RAP, IL33RPhase 3Chronic Obstructive Pulmonary Disease (COPD); Chronic Obstructive Pulmonary DiseaseJun 2027
Shanghai Zhongshan HospitalGene modified anti-IL1RAP Chimeric Antigen Receptor T Cells
IL1RAP-targeting CAR-T cell therapy
IL1RAPPhase 1HCCDec 2027
M.D. Anderson Cancer CenterNadunolimab
IL1RAP antibody
IL1RAPPhase 1Myelodysplastic Syndrome(MDS)Dec 2027
Dan FengNadunolimab
Anti-IL-1RAP antibody
IL1RAPPhase 1Metastatic Microsatellite Stable Colorectal CarcinomaDec 2028

Conditions

Generalized Pustular Psoriasis (2) Myelodysplastic Syndrome(MDS) (1) Pyoderma Gangrenosum (1) Chronic Obstructive Pulmonary Disease (COPD) (1) Chronic Obstructive Pulmonary Disease (1) HCC (1) Metastatic Microsatellite Stable Colorectal Carcinoma (1)

Modalities

mixed (2), antibody (2), other (1)

Companies

M.D. Anderson Cancer Center (1) LEO Pharma (1) Roche (1) Shanghai Zhongshan Hospital (1) Dan Feng (1)

Related targets

IL36R (1) IL33R (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.